Epigenetics of Prostate Cancer: Beyond DNA Methylation

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2006 Mar 28

PMID 16563224

Citations 50

Authors

W A Schulz

J Hatina

Affiliations

Soon will be listed here.

Abstract

Epigenetic mechanisms permit the stable inheritance of cellular properties without changes in DNA sequence or amount. In prostate carcinoma, epigenetic mechanisms are essential for development and progression, complementing, amplifying and diversifying genetic alterations. DNA hypermethylation affects at least 30 individual genes, while repetitive sequences including retrotransposons and selected genes become hypomethylated. Hypermethylation of several genes occurs in a coordinate manner early in carcinogenesis and can be exploited for cancer detection, whereas hypomethylation and further hypermethylation events are associated with progression. DNA methylation alterations interact with changes in chromatin proteins. Prominent alterations at this level include altered patterns of histone modification, increased expression of the EZH2 polycomb histone methyltransferase, and changes in transcriptional corepressors and coactivators. These changes may make prostate carcinoma particularly susceptible to drugs targeting chromatin and DNA modifications. They relate to crucial alterations in a network of transcription factors comprising ETS family proteins, the androgen receptor, NKX3.1, KLF, and HOXB13 homeobox proteins. This network controls differentiation and proliferation of prostate epithelial cells integrating signals from hormones, growth factors and cell adhesion proteins that are likewise distorted in prostate cancer. As a consequence, prostate carcinoma cells appear to be locked into an aberrant state, characterized by continued proliferation of largely differentiated cells. Accordingly, stem cell characteristics of prostate cancer cells appear to be secondarily acquired. The aberrant differentiation state of prostate carcinoma cells also results in distorted mutual interactions between epithelial and stromal cells in the tumor that promote tumor growth, invasion, and metastasis.

Citing Articles

Cellular and molecular aspects of drug resistance in cancers.

Shaik R, Malik M, Basavaraju S, Qurban J, Al-Subhi F, Badampudi S Daru. 2024; 33(1):4.

PMID: 39652186 PMC: 11628481. DOI: 10.1007/s40199-024-00545-8.

Advancements in Biomarkers of Prostate Cancer: A Review.

Agbetuyi-Tayo P, Gbadebo M, Rotimi O, Rotimi S Technol Cancer Res Treat. 2024; 23:15330338241290029.

PMID: 39440372 PMC: 11497500. DOI: 10.1177/15330338241290029.

Liquid Biomarkers in Prostate Cancer Diagnosis: Current Status and Emerging Prospects.

Liu Y, Hatano K, Nonomura N World J Mens Health. 2024; 43(1):8-27.

PMID: 38772530 PMC: 11704174. DOI: 10.5534/wjmh.230386.

ETV7 promotes colorectal cancer progression through upregulation of IFIT3.

Chai B, Li Y, Guo Y, Zhang Z, Jia K, Chai X Funct Integr Genomics. 2024; 24(1):8.

PMID: 38200280 PMC: 10781848. DOI: 10.1007/s10142-023-01282-y.

Epithelial-mesenchymal reprogramming by KLF4-regulated Rictor expression contributes to metastasis of non-small cell lung cancer cells.

Zhou H, Guan Q, Hou X, Liu L, Zhou L, Li W Int J Biol Sci. 2022; 18(13):4869-4883.

PMID: 35982899 PMC: 9379402. DOI: 10.7150/ijbs.73548.

References

Isaacs J . The biology of hormone refractory prostate cancer. Why does it develop?. Urol Clin North Am. 1999; 26(2):263-73. DOI: 10.1016/s0094-0143(05)70066-5. View

Shen M, Abate-Shen C . Roles of the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Dev Dyn. 2003; 228(4):767-78. DOI: 10.1002/dvdy.10397. View

Klezovitch O, Chevillet J, Mirosevich J, Roberts R, Matusik R, Vasioukhin V . Hepsin promotes prostate cancer progression and metastasis. Cancer Cell. 2004; 6(2):185-95. DOI: 10.1016/j.ccr.2004.07.008. View

Leman E, Madigan M, Brunagel G, Takaha N, Coffey D, Getzenberg R . Nuclear matrix localization of high mobility group protein I(Y) in a transgenic mouse model for prostate cancer. J Cell Biochem. 2003; 88(3):599-608. DOI: 10.1002/jcb.10368. View

Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N, Rotter V . Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene. 2004; 23(34):5759-69. DOI: 10.1038/sj.onc.1207706. View

Florl A, Steinhoff C, Muller M, Seifert H, Hader C, Engers R . Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer. 2004; 91(5):985-94. PMC: 2409889. DOI: 10.1038/sj.bjc.6602030. View

Dong J . Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Metastasis Rev. 2002; 20(3-4):173-93. DOI: 10.1023/a:1015575125780. View

van der Poel H . Smart drugs in prostate cancer. Eur Urol. 2003; 45(1):1-17. DOI: 10.1016/j.eururo.2003.08.011. View

Boyer L, Lee T, Cole M, Johnstone S, Levine S, Zucker J . Core transcriptional regulatory circuitry in human embryonic stem cells. Cell. 2005; 122(6):947-56. PMC: 3006442. DOI: 10.1016/j.cell.2005.08.020. View

10.

Olumi A, Grossfeld G, Hayward S, Carroll P, Tlsty T, Cunha G . Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999; 59(19):5002-11. PMC: 3300837. DOI: 10.1186/bcr138. View

11.

Filippova G, Qi C, Ulmer J, Moore J, Ward M, Hu Y . Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter tts DNA-binding specificity. Cancer Res. 2002; 62(1):48-52. View

12.

Kim M, Cardiff R, Desai N, Banach-Petrosky W, Parsons R, Shen M . Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S A. 2002; 99(5):2884-9. PMC: 122442. DOI: 10.1073/pnas.042688999. View

13.

Trotman L, Niki M, Dotan Z, Koutcher J, Di Cristofano A, Xiao A . Pten dose dictates cancer progression in the prostate. PLoS Biol. 2003; 1(3):E59. PMC: 270016. DOI: 10.1371/journal.pbio.0000059. View

14.

Robertson K . DNA methylation and human disease. Nat Rev Genet. 2005; 6(8):597-610. DOI: 10.1038/nrg1655. View

15.

Freestone S, Marker P, Grace O, Tomlinson D, Cunha G, Harnden P . Sonic hedgehog regulates prostatic growth and epithelial differentiation. Dev Biol. 2003; 264(2):352-62. DOI: 10.1016/j.ydbio.2003.08.018. View

16.

Schalken J, Bergh A, Bono A, Foster C, Gospadarowicz M, Isaacs W . Molecular prostate cancer pathology: current issues and achievements. Scand J Urol Nephrol Suppl. 2005; (216):82-93. DOI: 10.1080/03008880510030950. View

17.

Dammann R, Schagdarsurengin U, Seidel C, Strunnikova M, Rastetter M, Baier K . The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol. 2005; 20(2):645-63. DOI: 10.14670/HH-20.645. View

18.

Tsuchiya T, Tamura G, Sato K, Endoh Y, Sakata K, Jin Z . Distinct methylation patterns of two APC gene promoters in normal and cancerous gastric epithelia. Oncogene. 2000; 19(32):3642-6. DOI: 10.1038/sj.onc.1203704. View

19.

Masiello D, Chen S, Xu Y, Verhoeven M, Choi E, Hollenberg A . Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells. Mol Endocrinol. 2004; 18(10):2388-401. DOI: 10.1210/me.2003-0436. View

20.

Kurita T, Medina R, Mills A, Cunha G . Role of p63 and basal cells in the prostate. Development. 2004; 131(20):4955-64. DOI: 10.1242/dev.01384. View